吉非替尼治疗晚期非小细胞肺癌的临床观察  

Clinical Observation of Gefitinib in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：肖家雯[1] 孙素华[1] 鲍英春[1] 

机构地区：[1]沈阳市第五人民医院肿瘤内科,沈阳110023

出　　处：《中国现代医生》2009年第13期72-73,共2页China Modern Doctor

摘　　要：目的观察吉非替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法39例晚期NSCLC患者每日均口服吉非替尼250mg,直至病情进展或患者不能耐受时停药。结果39例患者中CR0例,PR12例(30.8%),有效率(CR+PR)30.8%,SD15例(38.5%),疾病控制率(CR+PR+SD)69.2%,1年生存率25.6%。最常见的毒副作用为皮疹18例(46.2%)、皮肤干燥11例(28.2%)和腹泻8例(20.5%)。结论吉非替尼治疗晚期NSCLC效果好,安全。Objective To evaluate the clinical efficacy and toxicity of gefitinib in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods 39 patients were treated with 250mg gifitinib every day until either disease progressed or severe side effects occurred. Results Among the 39 patients, complete response（ CR）and partial response（ PR）were 0.0% and 30.8%, and tumor response rate（ CR ＋ PR） was 30.8%;Stable disease （SD）was 38.5%;The disease control rate was 69.2%. Survival rate at 1 year was 25.6%. The major adverse events were rash（46.2%）,dry skin 28.2% and diarrhea 20.5%. Conclusion The treatment with gefitinib in patients with advanced non-small lung cancer is effective and safe.

关 键 词：吉非替尼 非小细胞肺癌 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]